Key facts
- This page summarizes Pascal Bamford's Form 3 filing for Akoya Biosciences, Inc. (AKYA).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 03 Sep 2024, 21:40.
Pascal Bamford - 29 Aug 2024 Form 3 Insider Report for Akoya Biosciences, Inc. (AKYA)
- Reporting relationship
- Chief Clinical Officer
- Issuer ticker
- AKYA
- Reported as of
- 29 Aug 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 03 Sep 2024, 21:40:25 UTC
- Next SEC filing
- 21 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Pascal Bamford by Brian McKelligon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Pascal Bamford filed Form 3 for Akoya Biosciences, Inc. (AKYA) on 03 Sep 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKYA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 82,758
- Date
- 29 Aug 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKYA
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- $13.34
- Footnotes
- F1
AKYA
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $12.30
- Footnotes
- F2
AKYA
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $5.96
- Footnotes
- F3
AKYA
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $5.35
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The option, representing a right to purchase a total of 150,000 shares, became exercisable as follows: one-fourth of the shares vested on September 20, 2022, and the remaining shares vested in 36 equal monthly installments beginning on October 20, 2022.
Footnote F2
The option, representing a right to purchase a total of 25,000 shares, became exercisable as follows: one-fourth of the shares vested on February 23, 2024 with the remaining shares vesting in 36 equal monthly installments beginning on March 23, 2024, subject to reporting person's continuous employment.
Footnote F3
The option, representing a right to purchase a total of 15,000 shares, became exercisable as follows: one-fourth of the shares vested on May 18, 2024 with the remaining shares vesting in 36 equal monthly installments beginning on June 18, 2024, subject to reporting person's continuous employment.
Footnote F4
The option, representing a right to purchase a total of 50,000 shares, becomes exercisable as follows: one-fourth of the shares vests on February 22, 2025 with the remaining shares vesting in 36 equal monthly installments beginning on March 22, 2025, subject to reporting person's continuous employment.